The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Correlation between overall response rate and progression-free survival/overall survival in comparative trials involving targeted therapies in molecularly enriched populations.
 
Benjamin J. Solomon
Honoraria - AstraZeneca; Bristol-Myers Squibb; Merck Sharp & Dohme; Pfizer; Roche/Genentech
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Loxo; Merck Sharp & Dohme; Pfizer (Inst); Roche/Genentech
Research Funding - Pfizer (Inst)
Patents, Royalties, Other Intellectual Property - Royalties from Veristrat (Biodesix); UpToDate
 
Herbert H. F. Loong
Consulting or Advisory Role - GlaxoSmithKline; Novartis; Roche/Genentech
Speakers' Bureau - Abbvie; Ignyta; Novartis
Research Funding - MSD Oncology (Inst)
Travel, Accommodations, Expenses - Bayer; MSD Oncology; Pfizer; Roche
 
Yvonne J. Summers
Honoraria - AstraZeneca; Bristol-Myers Squibb; Takeda
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb; Lilly; Novartis; Pfizer
Speakers' Bureau - AstraZeneca; Bristol-Myers Squibb; Takeda
Travel, Accommodations, Expenses - AstraZeneca; MSD; Roche
 
Zachary M Thomas
Employment - Lilly
Stock and Other Ownership Interests - Lilly
 
Pearl Plernjit French
Employment - Lilly
Stock and Other Ownership Interests - Lilly
 
Boris K. Lin
Employment - Lilly
Stock and Other Ownership Interests - Lilly
 
Andreas Sashegyi
Employment - Lilly
Stock and Other Ownership Interests - Lilly
 
Juergen Wolf
Honoraria - Abbvie; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; MSD; Novartis; Roche
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Blueprint Medicines; Boehringer Ingelheim; Bristol-Myers Squibb; Chugai Pharma; Ignyta; Janssen; Lilly; Loxo/Lilly; MSD Oncology; Novartis; Pfizer; Roche; Takeda
Research Funding - Bristol-Myers Squibb; Janssen; Novartis; Pfizer
 
James Chih-Hsin Yang
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Lilly; MSD; Novartis; Ono Pharmaceutical; Pfizer; Roche; Takeda
Consulting or Advisory Role - Abbvie; Amgen; Amgen; Astellas Pharma; AstraZeneca; AstraZeneca (Inst); Bayer; Blueprint Medicines; Boehringer Ingelheim; Boehringer Ingelheim (Inst); Bristol-Myers Squibb; Celgene; Clovis Oncology; Daiichi Sankyo; G1 Therapeutics; Hansoh; Incyte; Lilly; Merck Serono; MSD Oncology; Novartis; Ono Pharmaceutical; Pfizer; Roche/Genentech; Takeda; Yuhan
Travel, Accommodations, Expenses - Pfizer
 
Alexander E. Drilon
Honoraria - Foundation Medicine; Medscape; MORE Health; OncLive; Peerview; PeerVoice; Physicans' Education Resource; Research to Practice; Targeted Oncology
Consulting or Advisory Role - AstraZeneca; Bayer; BeiGene; BerGenBio; Blueprint Medicines; Exelixis; Genentech/Roche; Helsinn Therapeutics; Hengrui Therapeutics; Ignyta; Lilly; Loxo; MORE Health; Pfizer; Takeda/Millennium; TP Therapeutics; Tyra Biosciences; Verastem; Verastem
Research Funding - Foundation Medicine
Patents, Royalties, Other Intellectual Property - Wolters Kluwer (Royalties for Pocket Oncology)
Other Relationship - GlaxoSmithKline; Merck; Pfizer; PharmaMar; Puma Biotechnology; Taiho Pharmaceutical; Teva